Use of proton-pump inhibitors in early pregnancy and the risk of birth defects
- PMID: 21105793
- DOI: 10.1056/NEJMoa1002689
Use of proton-pump inhibitors in early pregnancy and the risk of birth defects
Abstract
Background: Symptoms of gastroesophageal reflux are common in pregnancy, but there are limited data on the risk of birth defects associated with exposure to proton-pump inhibitors (PPIs) in early pregnancy.
Methods: We conducted a cohort study to assess the association between exposure to PPIs during pregnancy and the risk of major birth defects among all infants born alive in Denmark between January 1996 and September 2008. We linked data from nationwide registries, including individual-level information on exposure to PPIs (prescriptions), birth defects, and potential confounders. Major birth defects, diagnosed within the first year of life, were categorized according to the standardized classification scheme of the European surveillance of congenital anomalies (EUROCAT). Our primary analyses assessed the use of PPIs from 4 weeks before conception through 12 weeks of gestation and from 0 through 12 weeks of gestation (first trimester).
Results: Among 840,968 live births, 5082 involved exposure to PPIs between 4 weeks before conception and the end of the first trimester of pregnancy. There were 174 major birth defects in infants whose mothers had been exposed to PPIs during this period (3.4%), as compared with 21,811 in the group whose mothers had not been exposed (2.6%) (adjusted prevalence odds ratio, 1.23; 95% confidence interval [CI], 1.05 to 1.44). In analyses limited to exposure during the first trimester, there were 118 major birth defects among 3651 infants exposed to PPIs (3.2%), and the adjusted prevalence odds ratio was 1.10 (95% CI, 0.91 to 1.34). The risk of birth defects was not significantly increased in secondary analyses of exposure to individual PPIs during the first trimester or in analyses limited to the offspring of women who had filled PPI prescriptions and received enough doses to have a theoretical chance of first-trimester exposure.
Conclusions: In this large cohort, exposure to PPIs during the first trimester of pregnancy was not associated with a significantly increased risk of major birth defects. (Funded by the Danish Medical Research Council and the Lundbeck Foundation.).
Comment in
-
Proton-pump inhibitors and birth defects--some reassurance, but more needed.N Engl J Med. 2010 Nov 25;363(22):2161-3. doi: 10.1056/NEJMe1009631. N Engl J Med. 2010. PMID: 21105800 No abstract available.
-
Proton pump inhibitors and safety during pregnancy.Gastroenterology. 2011 Jul;141(1):389-91. doi: 10.1053/j.gastro.2011.05.017. Epub 2011 May 26. Gastroenterology. 2011. PMID: 21620838 No abstract available.
-
ACP Journal Club. PPI use in the first trimester was not associated with increased risk for birth defects; PPI use 1 to 4 weeks before conception was.Ann Intern Med. 2011 Jun 21;154(12):JC6-11. doi: 10.7326/0003-4819-154-12-201106210-02011. Ann Intern Med. 2011. PMID: 21690589 No abstract available.
Similar articles
-
Prenatal exposure to acid-suppressive drugs and the risk of childhood asthma: a population-based Danish cohort study.Aliment Pharmacol Ther. 2012 May;35(10):1190-8. doi: 10.1111/j.1365-2036.2012.05073.x. Epub 2012 Mar 22. Aliment Pharmacol Ther. 2012. PMID: 22443179
-
Proton-pump inhibitors and birth defects--some reassurance, but more needed.N Engl J Med. 2010 Nov 25;363(22):2161-3. doi: 10.1056/NEJMe1009631. N Engl J Med. 2010. PMID: 21105800 No abstract available.
-
Maternal use of proton pump inhibitors during early pregnancy and the prevalence of hypospadias in male offspring.Am J Ther. 2014 Jul-Aug;21(4):254-9. doi: 10.1097/MJT.0b013e3182456a8f. Am J Ther. 2014. PMID: 22314213
-
Proton pump inhibitor use and enteric infections.Am J Gastroenterol. 2009 Mar;104 Suppl 2:S10-6. doi: 10.1038/ajg.2009.46. Am J Gastroenterol. 2009. PMID: 19262540 Review.
-
Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.Ann Pharmacother. 2010 Mar;44(3):572-6. doi: 10.1345/aph.1M519. Epub 2010 Feb 2. Ann Pharmacother. 2010. PMID: 20124466 Review.
Cited by
-
The Pathophysiological, Genetic, and Hormonal Changes in Preeclampsia: A Systematic Review of the Molecular Mechanisms.Int J Mol Sci. 2024 Apr 20;25(8):4532. doi: 10.3390/ijms25084532. Int J Mol Sci. 2024. PMID: 38674114 Free PMC article. Review.
-
Medication use before and during pregnancy in Japan: the Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study.Eur J Clin Pharmacol. 2024 Aug;80(8):1171-1180. doi: 10.1007/s00228-024-03685-7. Epub 2024 Apr 17. Eur J Clin Pharmacol. 2024. PMID: 38630193 Free PMC article.
-
Pregnancy Outcomes in Females with Eosinophilic Esophagitis: A Nationwide Population-Based Study.Inflamm Intest Dis. 2023 Oct 5;8(4):143-152. doi: 10.1159/000534412. eCollection 2023 Dec. Inflamm Intest Dis. 2023. PMID: 38115912 Free PMC article.
-
Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship.Indian J Gastroenterol. 2023 Oct;42(5):601-628. doi: 10.1007/s12664-023-01428-7. Epub 2023 Sep 12. Indian J Gastroenterol. 2023. PMID: 37698821 Review.
-
Drug-Induced Microbiome Changes: Considerations in Pregnancy.Am J Lifestyle Med. 2022 Oct 7;17(1):50-53. doi: 10.1177/15598276221130259. eCollection 2023 Jan-Feb. Am J Lifestyle Med. 2022. PMID: 36636397 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical